BioNTech and Pfizer will shortly be able to announce approval for their vaccine against the pathogen causing COVID-19 in the European Union. The European Medicines Agency EMA has just recommended conditional approval for the vaccine BNT162 in Amsterdam. This is not yet formally approved for the market – this can only be granted by the European Commission. However, this is usually based on the EMA recommendations.
Emergency approval for BNT162 for vaccinating people aged 16 and over from the EU is now expected shortly, possibly within 24 hours. Vaccinations against the SARS-CoV-2 virus should begin shortly thereafter in Europe.
For the stock market this is not a big surprise, it was generally expected that BioNTech’s BNT162 would receive EU approval. In the USA, however, there is currently a positive trend for BioNTech’s share price. The NASDAQ trading on Friday ended at $ 104.24; the pre-market indication in the US is currently at $ 108.50. With that beckon possible technical chart buy signals for the BioNTech share.